Developing new generation medicines for Central Nervous System (CNS) diseases and disorders with high unmet need
VistaGen Therapeutics (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company developing new generation medicines for multiple CNS diseases and disorders with high unmet need including major depressive disorder, social anxiety disorder and suicidal ideation.
Each of VistaGen's CNS pipeline candidates has potential as a convenient, at-home treatment with rapid-onset therapeutic benefits and an exceptional safety profile - without psychological or other side effects and safety concerns often associated with current and potential new generation medications for certain highly-prevalent CNS diseases and disorders.
Our Pipeline